Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
André J. Scheen. (2017) Pharmacological management of type 2 diabetes: what’s new in 2017?. Expert Review of Clinical Pharmacology 10:12, pages 1383-1394.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Articles from other publishers (15)
Changzhen Zhang, Guosheng Gao, Yafeng Li, Jingjing Ying, Jianhui Li & Supei Hu. (2023) Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity. Iranian Journal of Pharmaceutical Research 22:1.
Crossref
Crossref
Songmao Zheng, David Polidori, Yuanping Wang, Brian Geist, Xiefan Lin‐Schmidt, Jennifer L. Furman, Serena Nelson, Andrea R. Nawrocki & Simon A. Hinke. (2023)
A long‐acting
GDF15
analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model
. Clinical and Translational Science.
Crossref
Crossref
Yao Zhang, Yibing Wang & Junli Liu. (2023) Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective. Genes & Diseases 10:3, pages 825-847.
Crossref
Crossref
José L. Górriz, Irene Romera, Amelia Cobo, Phillipe D. O’Brien & Juan F. Merino-Torres. (2022) Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy 13:3, pages 389-421.
Crossref
Crossref
Huanbo Tan, Wencheng Su, Wenyu Zhang, Jie Zhang, Michael Sattler & Peijian Zou. (2021) Albumin-binding domain extends half-life of glucagon-like peptide-1. European Journal of Pharmacology 890, pages 173650.
Crossref
Crossref
Alina Kondrashina, Shauna Heffernan, Nora O’Brien & Linda Giblin. 2021. Biologically Active Peptides. Biologically Active Peptides
629
664
.
Huanbo Tan, Wencheng Su, Wenyu Zhang, Pengju Wang, Michael Sattler & Peijian Zou. (2019) Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins. Current Pharmaceutical Design 24:41, pages 4932-4946.
Crossref
Crossref
Raffaella Gentilella, Valeria Pechtner, Antonella Corcos & Agostino Consoli. (2019) Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes/Metabolism Research and Reviews 35:1, pages e3070.
Crossref
Crossref
Daoqi Tang, Hong Tian, Jicheng Wu, Jiaxiao Cheng, Cheng Luo, Wenbo Sai, Xiaoda Song, Xiangdong Gao & Wenbing Yao. (2018) C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. Journal of Pharmacological Sciences 138:1, pages 23-30.
Crossref
Crossref
Takahiro Yajima, Kumiko Yajima, Makoto Hayashi, Hiroshi Takahashi & Keigo Yasuda. (2018) Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. Journal of Diabetes and its Complications 32:3, pages 310-315.
Crossref
Crossref
Caina Li, Shaocong Hou, Shuainan Liu, Yi Huan, Sujuan Sun, Quan Liu & Zhufang Shen. (2017) The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
Ting-Ting Zhou, Fei Ma, Xiao-Fan Shi, Xin Xu, Te Du, Xiao-Dan Guo, Gai-Hong Wang, Liang Yu, Vatcharin Rukachaisirikul, Li-Hong Hu, Jing Chen & Xu Shen. (2017) DMT efficiently inhibits hepatic gluconeogenesis by regulating the Gαq signaling pathway. Journal of Molecular Endocrinology 59:2, pages 151-169.
Crossref
Crossref
Hiroaki Seino, Yukiko Onishi, Yusuke Naito & Mitsuhisa Komatsu. (2016) Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetology & Metabolic Syndrome 8:1.
Crossref
Crossref
Brian M Moran, Aine M McKillop & Finbarr PM O’Harte. (2016) Development of novel ligands for peptide GPCRs. Current Opinion in Pharmacology 31, pages 57-62.
Crossref
Crossref
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
Crossref